Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Progrediente Lungenfibrose unter Kombinationstherapie mit BCNU (1978)
    Springer
    Annals of hematology 36 (1978), S. 353-356 
    Details
    ISSN: 1432-0584
    Keywords: Side effects of cytotoxic therapy ; BCNU ; Acute leukaemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In two patients with acute leukaemia, the development of progressive interstitial pulmonary fibrosis was observed following chemotherapy with BCNU, Cytoxan and Ara-C. The x-ray changes were accompanied by restrictive changes of pulmonary function and, later on, by severe hypoxia. Serologic tests did not reveal infection with cytomegaly virus or mycoplasma pneumoniae. These findings, together with reports in the literature, suggest a toxic effect of BCNU on the lung. The combination with Cyclophosphamide may contribute to this toxic reaction.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01000593
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate (1988)
    Springer
    Journal of cancer research and clinical oncology 114 (1988), S. 95-100 
    Details
    ISSN: 1432-1335
    Keywords: Interferon plus MPA ; Advanced renal cell cancer ; Medroxyprogesterone acetate (MPA)
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%. Recently, interferon alpha (IFNα) was used for treatment of this disease in several studies which also demonstrated response rates of 15%. In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFNα 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial. The rIFNα 2C (2MU) was given s.c. 5 times per week for 8–12 weeks and subsequently once weekly until week 48. In the combined treatment, 750 mg MPA was given p. o. daily until week 48 in addition to the IFN as described. The overall response rate in 93 evaluable patients was 5.4%, corresponding to 2 complete and 3 partial responses. Median survival was 7 months in both treatment groups. These data confirm the ineffectivity of low IFN doses for treatment of RCC. The low response rate is not increased by addition of MPA to IFN. The analysis of other IFN studies suggests that not only IFN doses but also IFN sources may influence response rates in metastatic RCC.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00390492
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...